Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06136702 | ELEVATE Acceptability Study(ELEVATE AS) | unknown | N/A | 1,048 | University GhentOTHER | 4 | Nov 18, 2023 | clinicaltrials |
| NCT00997009 | Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer(MITO CERV 2) | unknown | Phase 2 | 108 | National Cancer Institute, NaplesOTHER | 1 | Nov 14, 2023 |
| NCT04070976 | Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer | unknown | N/A | 82 | National Institute of CancerologíaOTHER_GOV | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT05125380 | Cervical Cancer Screening by Self-sampling in a Cohort of Younger Women in Ethiopia | unknown | N/A | 1,200 | Lund UniversityOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06095674 | ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study(ITHACA) | unknown | Phase 1 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06095882 | Randomized Controlled, Open Clinical Study on Efficacy and Safety of Acupuncture for Bladder Function Recovery After Radical Cervical Cancer Surgery | unknown | N/A | 180 | Qilu Hospital of Shandong UniversityOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06068387 | A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis | unknown | N/A | 264 | Chongqing University Cancer HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03876860 | An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis | unknown | N/A | 118 | Margaret LiottaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06015360 | Fat Grafting for Vaginal Stenosis in Gynaelogical Cancer(GRASS) | unknown | N/A | 8 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT00923702 | Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India | unknown | Phase 4 | 22,729 | Partha BasuOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05805358 | Hyperpolarized 13C MRI for Cancer Immunotherapy(DNPSPIO) | unknown | Phase 2 | 90 | Chang Gung Memorial HospitalOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06016868 | Identification of a MOLecuLar Signature in Locally Advanced Cervical Cancer Patients(MOLLY) | unknown | — | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05318625 | A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRIUS Endoscope System in Laparoscopic Gynecological Surgery. | unknown | N/A | 30 | Precision Robotics (Hong Kong) LimitedINDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05904977 | Preliminary Study on the Metastatic Rate and Clinical Significance of the Anterior Leaf of Vesicouterine Ligament in Early Stage Cervical Cancer | unknown | — | 460 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05883670 | Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer | unknown | — | 118 | Shandong UniversityOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05879796 | Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer | unknown | — | 30 | Peking University Third HospitalOTHER | 0 | May 30, 2023 | clinicaltrials |
| NCT05606263 | Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer(GCR-05) | unknown | Phase 2 | 55 | Xi'an Jiaotong UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05863260 | Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer | unknown | — | 60 | Fudan UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05863377 | Efficacy of Chemotherapy Alone in Patients With Poor-differentiated Early-stage Cervical Cancer | unknown | — | 450 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05824494 | Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors | unknown | Phase 2 | 58 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT05812677 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05806125 | Clinical Value of the Fertility-preserving Surgery in Cervical Cancer | unknown | — | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT00492778 | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | unknown | Phase 2 | 165 | GOG FoundationNETWORK | 2 | Mar 29, 2023 | clinicaltrials |
| NCT05789628 | Discovering Factors in Cervical Cancer Patients' Clinical Trial Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 29, 2023 | clinicaltrials |
| NCT02599116 | Gastrointestinal Microbiome Study of Appendiceal Cancer | unknown | N/A | 24 | Mercy Medical CenterOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT01881659 | Cervical Cancer Screening With Human Papillomavirus Testing(ESTAMPA) | unknown | — | 50,000 | International Agency for Research on CancerOTHER | 9 | Mar 14, 2023 | clinicaltrials |
| NCT05193669 | Clinical Validation of Molecular Triage in HR-HPV Positive Women(VALTRIHP) | unknown | — | 23,941 | Hiantis SrlINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04689178 | Cervical Cancer Screening Uptake: A Randomised Controlled Trial Assessing the Effect of Sending Invitation Letters to Nonadherent Women(IMPACTGP) | unknown | N/A | 195,000 | Nantes University HospitalOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04704908 | Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) | unknown | — | 979 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04969445 | The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 647 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05045755 | The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 1,339 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05446883 | QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | unknown | Phase 3 | 498 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05602831 | Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer | unknown | — | 108 | Fudan UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05437692 | Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05570331 | Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women | unknown | — | 2,200 | Ding MaOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05561413 | Gynaecology Exercise and Mindfulness Study(GEMS) | unknown | N/A | 40 | University of UlsterOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05560035 | The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery | unknown | N/A | 60 | General Hospital of Ningxia Medical UniversityOTHER | 0 | Sep 29, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05532930 | An Exploratory Study of Using Magnetic Resonance Prognostic Imaging Markers for Radiotherapy In Patients With Cervix Cancer (EMPIRIC Study)(EMPIRIC) | unknown | — | 40 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | unknown | Phase 2 | 28 | Saitama Medical University International Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05475847 | Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer(TIL) | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05247619 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 49 | Zhejiang Cancer HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05444374 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 48 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05122221 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | unknown | Phase 1 | 12 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2023source: clinicaltrials